ClinicalTrials.gg
Active, not recruitingNCT06557772Updated Aug 31, 2026

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

A Phase 2 interventional study of Amlitelimab and Placebo in Coeliac Disease and Celiac Disease, sponsored by Sanofi. Active, not recruiting at 118 sites in 21 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
6th of 68
229 · median 46
Started
2024
with 4 others
Phase 2
21 of 103
1 open now
Primary completion
2026-08
later than 3 of 19 live
Registered
95th of 103
by date

Among the 103 studies in Celiac Disease with a site in United States, this one is the 6th largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2024, is one of 21 in phase 2, reaches primary completion later than 3 of the 19 other live ones, and was the 95th registered.

Celiac Disease

352 studies on the registry are indexed under Celiac Disease; 77 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE).

The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will assess the effect of amlitelimab when compared to placebo on gluten induced changes in the intestinal mucosa as measured by the villous height to crypt depth (Vh:Cd) ratio. The effect of amlitelimab on participant-reported celiac signs and symptoms along with the safety, tolerability, and pharmacokinetics of amlitelimab will also be studied.

Study details include:

The study duration will be up to 48 weeks (including a 16-week safety follow-up period) with 10 visits for participants who opt not to enter the optional long-term extension.

The study duration will be up to 172 weeks (including an 8-week safety follow-up period) with 22 visits for participants who enter the optional long-term extension.

The double-blind placebo-controlled treatment duration will be up to 28 weeks.

03

Conditions studied

  • Coeliac Disease
  • Celiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 to 75 years of age inclusive, at the time of signing the .
  • Participants with physician-diagnosed celiac disease with documented history of -proven celiac disease confirmed by medical records or physician statement.
  • Participants who have self-reported attempt to maintain a GFD (and confirmed via questionnaire) for at least 12 consecutive months and must be willing to maintain their current diet for the duration of study participation.
  • Participants have an adequate comprehension of a GFD as assessed by the Investigator.
  • Participants willing to undergo all assessments in the protocol, including 2 esophagogastroduodenoscopies with duodenal biopsies.
  • Participants who completed CDSD with ≥ 75% compliance from screening until randomization.
  • During screening, participants must have at least one gastrointestinal symptom (i.e., diarrhea, abdominal pain, bloating, or nausea) of moderate or greater severity, as measured by the CDSD Gastrointestinal Domain, on at least 3 days out of any consecutive 7-day period considered by the investigator to be related to gluten exposure (i.e., due to celiac disease). The symptom can vary, but severity must be moderate or greater on three or more days. Participants must meet symptom criteria to undergo baseline esophagogastroduodenoscopy (EGD).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • A diagnosis of any severe complication of celiac disease, such as celiac disease type 1 (RCD I) requiring immune suppressive medication, or type 2 (RCD II), enteropathy associated T-cell lymphoma (EATL), ulcerative jejunitis, or recent (within 12 months of screening) GI perforation.
  • Presence of other active inflammatory GI disorders, including but not limited to the following: inflammatory bowel disease, eosinophilic esophagitis, diverticulitis, helicobacter infection, gastroenteritis or colitis, and microscopic colitis (requiring treatment) in the 6 months before screening. A history of treated erosive esophagitis is not an exclusion. Abnormalities found during baseline EGD or that are consistent with an inflammatory GI disorder other than celiac disease are exclusionary.
  • Presence of other systemic diseases including scleroderma, psoriatic or rheumatoid arthritis, and lupus. Participants with thyroid disease that has been well-controlled for at least 6 months, prior to screening, and participants with well-controlled type 1 diabetes (glycosylated \< 9 % and no hospitalization or emergency room visit in the last 12 months for hyperglycemia or hypoglycemia) can be included per investigator judgement.
  • Known or suspected severe enteric infection (viral, bacterial, or parasitic) within 6 months before screening. Severe enteric infection is defined as requiring a visit to the emergency room, hospitalization, or treatment with antibiotics or anti-infectives due to infection. Non-enteric viral infections, either resolved or well-controlled are not exclusionary.
  • Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to screening (1 week in the event of superficial skin infections).
  • Known history of or suspected significant current or hyposplenism, including history of invasive opportunistic or invasive helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • Any or history of malignancies prior to enrollment (except for non-melanoma skin cancer that has been excised and completely cured for more than 5 years prior to enrollment).
  • History of solid organ or stem cell transplant.
  • Ongoing use, or use in the 3 months before screening, of medications known to cause villus abnormalities (eg, mycophenolate mofetil, azathioprine, methotrexate, olmesartan (other angiotensin receptor blockers are allowed), CTLA4 inhibitors, and /PD-L1 inhibitors).
  • Ongoing chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) of more than 2 doses per week, except acetylsalicylic acid/aspirin ≤100 mg daily for prophylactic use.
  • Any ongoing treatment with systemic immunosuppressants, systemic , or use of oral budesonide in the 12 weeks before screening.
  • Ongoing use of over-the-counter digestive enzymes or supplements, other than lactase, including those for gluten digestion and oral pharmaceutical probiotic supplements. Probiotics in foods (e.g., yogurt) are permitted.
  • Concurrent participation in any other clinical study, including non-interventional studies.
  • Prior administration of agents to treat celiac disease within 5 half-lives of any agent, or one year from any tolerogenic agent.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    Amlitelimab dose 1 + Gluten-free product (GFP)

    Amlitelimab SC as per protocol + GFP

    Drug: Amlitelimab · Dietary Supplement: Gluten-free product (GFP)

  • Experimental
    Amlitelimab dose 2 + GFP

    Amlitelimab SC as per protocol + GFP

    Drug: Amlitelimab · Dietary Supplement: Gluten-free product (GFP)

  • Experimental
    Amlitelimab dose 3 + GFP

    Amlitelimab SC as per protocol + GFP

    Drug: Amlitelimab · Dietary Supplement: Gluten-free product (GFP)

  • Experimental
    Amlitelimab dose 1 + SIGE

    Amlitelimab SC as per protocol + SIGE

    Drug: Amlitelimab · Dietary Supplement: SIGE

  • Placebo comparator
    Placebo + GFP

    Placebo SC as per protocol + GFP

    Drug: Placebo · Dietary Supplement: Gluten-free product (GFP)

  • Placebo comparator
    Placebo + SIGE

    Placebo SC as per protocol + SIGE

    Drug: Placebo · Dietary Supplement: SIGE

Interventions

  • Pharmaceutical form: Injection solution Route of administration: SC injection

    Also known as: SAR445229

  • DrugPlacebo

    Pharmaceutical form: Injection solution Route of administration: SC injection

  • Dietary supplementSIGE

    Pharmaceutical form: Capsule Route of administration: Oral

  • Dietary supplementGluten-free product (GFP)

    Pharmaceutical form: Capsule Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Change in Villus Height to Crypt Depth Ratio (Vh:Cd) from baseline to Week 28

    Change in Vh:Cd ratio.

    Time frame: Baseline to Week 28

Secondary outcomes

  1. Change in Celiac Disease Symptom Diary (CDSD) Gastrointestinal (GI) symptom severity score

    The CDSD is a patient report outcome instrument that assesses common celiac symptoms (abdominal pain, bloating, tiredness, nausea, and diarrhea). GI symptom severity score ranges from 0-20 with higher score indicating more severe disease.

    Time frame: Baseline to Week 28

  2. Percentage of participants who experienced treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESI) during the placebo-controlled treatment period and the long-term extension

    Time frame: Baseline to Week 168

  3. Percentage of participants with potentially clinically significant abnormalities (PCSA) for vital signs and clinical laboratory assessments during the placebo-controlled treatment period and the long-term extension

    Time frame: Baseline to Week 168

  4. Percentage of participants discontinued from study treatment due to TEAEs during the placebo-controlled treatment period and the long-term extension

    Time frame: Baseline to Week 168

  5. Serum amlitelimab concentrations measured at prespecified timepoints

    Time frame: Baseline to Week 168

  6. Incidence of antidrug antibodies (ADAs) of amlitelimab

    Time frame: Baseline to Week 168

07

Study locations

118 sites
  • One of a Kind Clinical Research Center - Scottsdale- Site Number : 8400055
    Scottsdale, Arizona 85253, United States
  • FOMAT Medical Research - inSite Digestive Health Care - Arcadia- Site Number : 8400052
    Arcadia, California 91006, United States
  • Om Research- Site Number : 8400001
    Lancaster, California 93534, United States
  • United Medical Doctors - Los Alamitos- Site Number : 8400014
    Los Alamitos, California 90720, United States
  • Om Research- Site Number : 8400010
    Oxnard, California 93030, United States
  • Advanced Research Institute - Denver- Site Number : 8400048
    Denver, Colorado 80218, United States
  • Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400040
    Miami Lakes, Florida 33016, United States
  • Center for Digestive Health- Site Number : 8400013
    Orlando, Florida 32803, United States
  • GCP Clinical Research- Site Number : 8400007
    Tampa, Florida 33609, United States
  • Treasure Valley Medical Research- Site Number : 8400006
    Boise, Idaho 83706, United States
  • Hutchinson Clinic- Site Number : 8400020
    Hutchinson, Kansas 67502, United States
  • University of Kansas Medical Center- Site Number : 8400041
    Kansas City, Kansas 66160, United States
  • Boston Specialists- Site Number : 8400051
    Boston, Massachusetts 02111, United States
  • Berkshire Medical Center- Site Number : 8400017
    Pittsfield, Massachusetts 01201, United States
  • Gastroenterology Associates of Western Michigan - Wyoming- Site Number : 8400004
    Wyoming, Michigan 49519, United States
  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400049
    Rochester, Minnesota 55905, United States
  • Washington University- Site Number : 8400025
    St Louis, Missouri 63110, United States
  • Advanced Research Institute - Reno- Site Number : 8400036
    Reno, Nevada 89511, United States
  • Sanmora Bespoke Clinical Research Solutions- Site Number : 8400015
    East Orange, New Jersey 07018, United States
  • Allied Digestive Health - Middlesex Monmouth Gastroenterology- Site Number : 8400053
    Freehold, New Jersey 07728, United States
  • M3 Wake Research- Site Number : 8400008
    Raleigh, North Carolina 27612, United States
  • Thomas Jefferson University Hospital- Site Number : 8400056
    Philadelphia, Pennsylvania 19107, United States
  • Velocity Clinical Research - Providence- Site Number : 8400002
    East Greenwich, Rhode Island 02818, United States
  • M3 Wake Research - Chattanooga- Site Number : 8400012
    Chattanooga, Tennessee 37421, United States
  • Quality Medical Research- Site Number : 8400018
    Nashville, Tennessee 37211, United States
  • Texas Digestive Disease Consultants - Cedar Park- Site Number : 8400030
    Cedar Park, Texas 78613, United States
  • MedCare Pharma - Houston - Cypress Creek Parkway- Site Number : 8400016
    Houston, Texas 77090, United States
  • LinQ Research - Smith Ranch Road- Site Number : 8400028
    Pearland, Texas 77584, United States
  • DM Clinical Research - Tomball- Site Number : 8400042
    Tomball, Texas 77375, United States
  • Advanced Research Institute - Odgen- Site Number : 8400044
    Ogden, Utah 84405, United States
  • Advanced Research Institute - Sandy - South 1300 East- Site Number : 8400046
    Sandy City, Utah 84094, United States
  • Velocity Clinical Research - Salt Lake City- Site Number : 8400023
    West Jordan, Utah 84088, United States
  • Gastroenterology Associates of Central Virginia- Site Number : 8400057
    Lynchburg, Virginia 24502, United States
  • Clinical Research Partners - Richmond - Forest Avenue- Site Number : 8400011
    Richmond, Virginia 23220, United States
  • GI Alliance - Tacoma- Site Number : 8400033
    Tacoma, Washington 98405, United States
  • Investigational Site Number : 0320010
    Quilmes, Buenos Aires 1878, Argentina
  • Investigational Site Number : 0320008
    San Isidro, Buenos Aires 1642, Argentina
  • Investigational Site Number : 0320012
    Buenos Aires, Buenos Aires F.D. 1061, Argentina
  • Investigational Site Number : 0320005
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320002
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigational Site Number : 0320007
    Buenos Aires, 1006, Argentina
  • Investigational Site Number : 0320009
    Buenos Aires, 1119, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1128, Argentina
  • Investigational Site Number : 0320003
    Córdoba, 5000, Argentina
  • Investigational Site Number : 0360002
    Sydney, New South Wales 2560, Australia
  • Investigational Site Number : 0360001
    Mackay, Queensland 4740, Australia
  • Investigational Site Number : 0360005
    Melbourne, Victoria 3128, Australia
  • Investigational Site Number : 0560002
    Brussels, 1200, Belgium
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Hospital Sao Rafael- Site Number : 0760005
    Salvador, Estado de Bahia 41253-190, Brazil
  • Centro de Pesquisas da Clínica IBIS- Site Number : 0760006
    Salvador, Estado de Bahia 41820-020, Brazil
  • Chronos Pesquisa Clínica- Site Number : 0760002
    Brasília, Federal District 72145-450, Brazil
  • Hospital Moinhos de Vento- Site Number : 0760004
    Porto Alegre, Rio Grande do Sul 90035-902, Brazil
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Praxis Pesquisas Medicas- Site Number : 0760008
    Santo André, São Paulo 09090-790, Brazil
  • Investigational Site Number : 1240001
    Vancouver, British Columbia V6Z 2K5, Canada
  • Investigational Site Number : 1240002
    Victoria, British Columbia V8V 3M9, Canada
  • Investigational Site Number : 1520006
    Concepción, Biobio 4070038, Chile
  • Investigational Site Number : 1520005
    Talcahuano, Biobio 2687000, Chile
  • Investigational Site Number : 1520007
    Santiago, Reg Metropolitana de Santiago 7510086, Chile
  • Investigational Site Number : 1520004
    Santiago, Reg Metropolitana de Santiago 7620001, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8330034, Chile
  • Investigational Site Number : 1520008
    Santiago, Reg Metropolitana de Santiago 8331143, Chile
  • Investigational Site Number : 2030002
    Brno, 636 00, Czechia
  • Investigational Site Number : 2030006
    Havířov, 736 01, Czechia
  • Investigational Site Number : 2030005
    Klatovy, 339 01, Czechia
  • Investigational Site Number : 2030001
    Prague, 118 33, Czechia
  • Investigational Site Number : 2030003
    Prague, 150 06, Czechia
  • Investigational Site Number : 2460002
    Helsinki, 00180, Finland
  • Investigational Site Number : 2460003
    Helsinki, 00270, Finland
  • Investigational Site Number : 2460001
    Turku, 20520, Finland
  • Investigational Site Number : 2500002
    Nice, 06202, France
  • Investigational Site Number : 2500001
    Paris, 75015, France
  • Investigational Site Number : 2760006
    Berlin, 10117, Germany
  • Investigational Site Number : 2760004
    Berlin, 12203, Germany
  • Investigational Site Number : 2760001
    Halle, 06108, Germany
  • Investigational Site Number : 2760002
    Mainz, 55131, Germany
  • Investigational Site Number : 3000001
    Athens, 106 76, Greece
  • Investigational Site Number : 3000002
    Athens, 115 27, Greece
  • Investigational Site Number : 3760002
    Afula, 1834111, Israel
  • Investigational Site Number : 3760006
    Beersheba, 8457108, Israel
  • Investigational Site Number : 3760004
    Jerusalem, 9103102, Israel
  • Investigational Site Number : 3760003
    Petah Tikva, 4941492, Israel
  • Investigational Site Number : 3760007
    Ramat HaSharon, 4731001, Israel
  • Investigational Site Number : 3760001
    Rehovot, 7610001, Israel
  • Ospedale Maggiore Policlinico Milano-Site Number : 3800002
    Milan, Milano 20122, Italy
  • Azienda Ospedaliera di Padova-Site Number : 3800004
    Padua, Padova 35128, Italy
  • Ospedale di Cisanello-Site Number : 3800003
    Pisa, 56124, Italy
  • Investigational Site Number : 5280001
    Amsterdam, 1081 HV, Netherlands
  • Investigational Site Number : 5280002
    Arnhem, 6815 AD, Netherlands
  • Investigational Site Number : 6160004
    Poznan, Greater Poland Voivodeship 60-529, Poland
  • Investigational Site Number : 6160001
    Krakow, Lesser Poland Voivodeship 31-501, Poland
  • Investigational Site Number : 6160005
    Wroclaw, Lower Silesian Voivodeship 50-088, Poland
  • Investigational Site Number : 6160002
    Warsaw, Masovian Voivodeship 02-507, Poland
  • Investigational Site Number : 7030001
    Košice, 040 13, Slovakia
  • Investigational Site Number : 7030003
    Nitra, 950 01, Slovakia
  • Investigational Site Number : 7030004
    Šahy, 936 01, Slovakia
  • Investigational Site Number : 7240006
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number : 7240009
    Chiclana de la Frontera, Cádiz 11139, Spain
  • Investigational Site Number : 7240011
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain

Showing the first 100 of 118 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2026, 23 months.

Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 16, 2024
StartActual
Aug 29, 2024
Primary completionActual
Aug 5, 2026
CompletionEst.
Apr 10, 2029
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06557772
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Aug 29, 2024
Primary completion
Aug 5, 2026
Completion
Apr 10, 2029 (estimated)
Last update
Aug 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion